NuVasive, Inc. (NUVA): Price and Financial Metrics

NuVasive, Inc. (NUVA): $59.07

-1.42 (-2.35%)

POWR Rating

Component Grades














  • NUVA scores best on the Growth dimension, with a Growth rank ahead of 99.1% of US stocks.
  • The strongest trend for NUVA is in Stability, which has been heading up over the past 47 weeks.
  • NUVA's current lowest rank is in the Sentiment metric (where it is better than 13.79% of US stocks).

NUVA Stock Summary

  • With a one year PEG ratio of 3,233.27, Nuvasive Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.92% of US stocks.
  • NUVA's current price/earnings ratio is 1,612.96, which is higher than 99.74% of US stocks with positive earnings.
  • Nuvasive Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 21.83%, greater than the shareholder yield of 89.75% of stocks in our set.
  • Stocks that are quantitatively similar to NUVA, based on their financial statements, market capitalization, and price volatility, are CPIX, POWL, OPRX, FMX, and AVNS.
  • NUVA's SEC filings can be seen here. And to visit Nuvasive Inc's official web site, go to

NUVA Valuation Summary

  • In comparison to the median Healthcare stock, NUVA's price/sales ratio is 75.33% lower, now standing at 2.8.
  • NUVA's price/earnings ratio has moved up 1755.3 over the prior 211 months.
  • NUVA's price/sales ratio has moved down 7.5 over the prior 211 months.

Below are key valuation metrics over time for NUVA.

Stock Date P/S P/B P/E EV/EBIT
NUVA 2021-08-31 2.8 3.8 1732.5 64.8
NUVA 2021-08-30 2.7 3.7 1656.7 62.5
NUVA 2021-08-27 2.7 3.7 1671.8 63.0
NUVA 2021-08-26 2.7 3.6 1651.7 62.4
NUVA 2021-08-25 2.6 3.6 1643.6 62.2
NUVA 2021-08-24 2.7 3.7 1673.4 63.0

NUVA Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at 85.09%.
  • The 5 year revenue growth rate now stands at 44.12%.
  • The 5 year price growth rate now stands at 20.62%.
NUVA's revenue has moved up $68,127,000 over the prior 33 months.

The table below shows NUVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1,153.166 232.2 1.853
2021-03-31 1,061.95 212.325 -49.961
2020-12-31 1,050.582 185.911 -37.153
2020-09-30 1,069.129 187.903 -8.969
2020-06-30 1,064.682 174.966 -3.831
2020-03-31 1,153.175 216.04 61.146

NUVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NUVA has a Quality Grade of C, ranking ahead of 61.4% of graded US stocks.
  • NUVA's asset turnover comes in at 0.477 -- ranking 98th of 182 Medical Equipment stocks.
  • XENT, IRMD, and ALGN are the stocks whose asset turnover ratios are most correlated with NUVA.

The table below shows NUVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.477 0.723 0.034
2021-03-31 0.418 0.697 0.001
2020-12-31 0.411 0.694 0.014
2020-09-30 0.454 0.700 0.027
2020-06-30 0.495 0.706 0.028
2020-03-31 0.595 0.731 0.088

NUVA Price Target

For more insight on analysts targets of NUVA, see our NUVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $73.69 Average Broker Recommendation 1.79 (Moderate Buy)

NUVA Stock Price Chart Interactive Chart >

Price chart for NUVA

NUVA Price/Volume Stats

Current price $59.07 52-week high $72.61
Prev. close $60.49 52-week low $43.11
Day low $58.77 Volume 634,000
Day high $60.17 Avg. volume 651,255
50-day MA $61.44 Dividend yield N/A
200-day MA $61.87 Market Cap 3.05B

NuVasive, Inc. (NUVA) Company Bio

NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.

NUVA Latest News Stream

Event/Time News Detail
Loading, please wait...

NUVA Latest Social Stream

Loading social stream, please wait...

View Full NUVA Social Stream

Latest NUVA News From Around the Web

Below are the latest news stories about Nuvasive Inc that investors may wish to consider to help them evaluate NUVA as an investment opportunity.

NuVasive Simplify Cervical Disc Data Published In International Journal Of Spine Surgery

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify® Cervical Disc one-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the International Journal of Spine Surgery. The data was utilized in the device's FDA pre-market application for one-level indication approval in S

Yahoo | September 9, 2021

Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia to the Board of Directors

Kadia joins Board as an Independent Director who brings significant expertise in commercializing disruptive life science technologiesEMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that Siddhartha Kadia, Ph.D. joined the Berkeley Lights Board of Directors as an independent director, effective September 7, 2021. “I am excited to join the Berkeley Lights Board of Directors," said Dr. Kadia. "I am passiona

Yahoo | September 9, 2021

NuVasive's (NASDAQ:NUVA) investors will be pleased with their 18% return over the last year

We believe investing is smart because history shows that stock markets go higher in the long term. But if when you...

Yahoo | September 6, 2021

NuVasive (NUVA) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Yahoo | September 6, 2021

NuVasive Announces New Executive Leadership Roles

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced new executive leadership roles, strengthening its innovation and go-to-market teams while furthering the Company's growth. Effective immediately, Massimo Calafiore has been appointed Chief Commercial Officer, and Ryan Donahoe has been appointed Chief Technology Officer, both reporting directly to Chief Execut

Yahoo | September 1, 2021

Read More 'NUVA' Stories Here

NUVA Price Returns

1-mo -1.20%
3-mo -10.89%
6-mo -11.94%
1-year 8.05%
3-year -15.52%
5-year -10.58%
YTD 4.86%
2020 -27.17%
2019 56.05%
2018 -15.27%
2017 -13.17%
2016 24.49%

Continue Researching NUVA

Here are a few links from around the web to help you further your research on Nuvasive Inc's stock as an investment opportunity:

Nuvasive Inc (NUVA) Stock Price | Nasdaq
Nuvasive Inc (NUVA) Stock Quote, History and News - Yahoo Finance
Nuvasive Inc (NUVA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8592 seconds.